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Good practice in the postmarketing surveillance of medicines
• R .H .B. Meyboom
Introduction
It is now generally recognized and accepted that 
there is a need for Good Clinical Trial Practice (GCP), 
to ensure that clinical drug trials are, in ethical and 
scientific respects, properly conducted [1 2], It has 
taken decades, however, until general agreement 
with regard to GCP was reached. A clinical trial con­
cerns a medically very delicate situation; the use of an 
experimental treatment, simultaneously aiming at the 
cure (or diagnosis) of a patient and the demonstra­
tion of the efficacy and safety of that treatment. GCP 
is primarily concerned with the protection of the 
rights, interests and responsibilities of individuals, i.e. 
patients, investigators, and (often) the pharmaceuti­
cal company concerned, important interests of the 
patients are the informed consent procedure, justifi­
cation of predictable risks and inconveniences, scien­
tific efficiency (i.e. the potential for reaching sound 
conclusions with the smallest amount of data), and 
appropriate measures with regard to treatment, insu­
rance and compensation if a serious untoward effect 
occurs. Ethics committees ensure that trials are con­
ducted according to GCP and to the Declaration of 
Helsinki (World Medical Association, June 1964). 
When a patient has consented to participate in a trial, 
ail (anonymised) data relevant to his treatment are 
assumed to become the property of the investigator 
or sponsor of the study. The development of new 
medicines and the scientific quality of clinical trials are 
obviously of great importance to public health, but in 
GCP the public interest is only a secondary issue. 
When a new drug is approved there is sufficient 
knowledge available to enable appropriate decision 
making regarding the treatment of individual 
patients. Paradoxically but inevitably, however, there 
is at the same time often some uncertainty with 
regard to the possible side effects of the drug or its 
safety (and efficacy) in the long term use in the popu­
lation at large. Much of our knowledge of medicines 
comes available only during the years after introduc­
tion. To illustrate this, in table 1 a review is given of 
aspects of marketed medicines that often need fur­
ther study. The clinical trial is a well developed and 
understood instrument [3]. The study of marketed 
medicines, on the other hand, is still in a develop­
mental stage and many problems involved have only 
partly been solved.
Postm arketing surveillance
The Health Council in the Netherlands has defined 
postmarketing surveillance (PMS) as 'the systematic 
surveillance and scientific study of all intended and 
unintended effects of medicines on human health, 
after their release for marketing' [4]. It was added that 
'its aim is to obtain data of scientific quality for the 
rational and safe use of medicines'. In this definition 
and in the context of this paper PMS refers to phar- 
macovigilance as well as to pharmacoepidemiology.
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In addition to Good Clinical Trial Practice for the study of 
experimental drugs, regulations are also needed for good 
practice in the assessment of medicines after approval (Good 
PMS Practice, GPP). GPP has to protect the interests of public 
health at large as well as those of individual patients, investi­
gators and pharmaceutical companies. GPP may be the natu­
ral way to solve threatening conflicts between privacy legisla­
tion and the public interest.
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Table 1 Review of subjects of interest in the post

















Fine-tuning of dosage recommendations 
Reappraisal of indications (extension or 
restriction)
Drug use and drug users characteristics 
Assessment of long-term efficacy (e.g. in the 
case of surrogate endpoints)
Assessment of side effects:
Detection of unexpected side effects and 
interactions
identification of risk factors 
Quantitative measurement of (un)safety 
Long term safety/toxicity 
Study of potential risk groups (e.g. children, 
elderly, pregnancy)
Detection of unexpected beneficial effects 
Further pharmacological and mechanistic 
studies
Detection of pharmaceutical defects and 
couterfeit drugs
Dangers of misuse (intentional and acciden­
tal intoxication, dependence)
Quality of life and utility assessment 
Collection of data needed for cost assess­
ment
The term pharmacovigilance is often used more spe­
cifically for the detection and prevention of adverse 
reactions [5], i.e. monitoring and early warning. PMS 
faces many different problems, of scientific, ethical, 
logistic, legal and financial nature. Through the years 
a variety of methods and systems have been devel­
oped, which can roughly be distinguished into 'spon­
taneous reporting' in all its different shapes, and the 
various epidemiological approaches (see table 2) [6- 
8], All have specific advantages and shortcomings 
and new ways may be envisaged in the future. 
Spontaneous reporting, for example, is mainly effec­
tive in the detection of characteristic adverse reac­
tions with a suggestive time relationship but is of lim­
ited use in estimating reaction frequency [9]. PMS is 
still under development and there is as yet some 
uncertainty into how much detail we will - scientifical­
ly, ethically and financially - be able to measure the 
balance of benefits and risks of medicines. For less 
affluent countries, the exact and costly measurement 
of the risks of efficacious drugs may even remain a 
luxury.
Table 2 Methods for studying marketed medi­
cines [6-8]
1. Spontaneous reporting
2. Intensive hospital monitoring
3. Prescription event monitoring
4. Case control studies and case control surveil­
lance
5. Follow-up studies (with or without control 
group)
6. Record linkage and large linked data resources
7. Drug use and users studies
8. Studies using disease registers
Burden of proof
At the moment when a medicine is approved by the 
competent authority many changes take place. The 
drug is no longer experimental but has (legally) 
become an established treatment. Its users no longer 
are experimental patients, monitored by the precau­
tions of the trial and the provisions of GCP. Instead, 
the experiences with the drug are from now on more 
or less hidden from view because of medical and 
pharmaceutical secrecy. From the medical point of 
view, on the other hand, a new drug only slowly loos­
es its experimental character during the years after 
introduction.
Before the registration of a medicine, the company 
has to meet the requirements put forward by the reg­
ulatory authority and to provide any data requested. 
If the data are not satisfactory, additional evidence 
must be produced by the company. Once the drug is 
registered, however, in many countries the burden of 
proof moves from the company to the registration 
authority. New in European Union legislation is that a 
marketing authorization is valid for a period of five 
years [10]. The authorization will be renewable for 
subsequent five years periods upon application by the 
company, accompanied by a dossier contain up-to- 
date information on pharmacovigilance in the form of 
periodic safety updates. It is not clear, however, if the 
European authority can demand the conduction of 
additional studies (e.g. for the testing of hypotheses 
regarding adverse reactions).
Differences between countries 
Since the pioneering WHO Technical Reports [11], 
the principles of spontaneous reporting have been 
reviewed in several articles and books [6-8 12-17]. 
Somewhat different procedures have, however, devel­
oped in different countries [7 18] and different views 
exist with regard to important issues such as causality 
assessment [19], confidentiality, freedom of informa­
tion, and reporting obligations. The Dutch Health 
Council has published a special report on 'Privacy in 
Postmarketing Surveillance', in which the need for 
anonymity of case reports is emphasized [20]. In the 
draft European Guideline on adverse reaction report­
ing, on the other hand, it is explicitly requested that 
case reports contain the surname and first names of 
the patients (although the provision 'if available and 
acceptable under national law' is added) [21]. New 
regulations in the European Union give companies 
and governments obligations with regard to the 
reporting of suspected adverse reactions [21-23]. In 
many countries in and outside the European Union 
reporting obligations do not exist, however, for physi­
cians and pharmacists, i.e. those who actually observe 
patients with adverse reactions in practice. The num­
ber of countries, on the other hand, where adverse 
reactions reporting has become mandatory also to 
health care professionals is increasing.
In many countries (anonymised) data obtained 
through spontaneous reporting are publicly available 
under the freedom of information act (e.g. Australia, 
Canada, Nordic countries, USA). In other countries 
(e.g. France, Germany, UK), on the other hand, the 
data are confidential, in common with the registra­
tion file.
Problems
After approval of a drug also the study environment 
and scientific principles change. In PMS the users 
population and study parameters are not defined and 
fixed (as in a clinical trial) but, on the contrary, are 
unselected and open. PMS needs to be non-interven­
tional, i.e. prescriber may not be influenced in their 
choice of a drug during data collection for PMS and a 
treatment may not be changed for the purpose of 
PMS. A characteristic feature of PMS is that, as com­
pared with a clinical trial, often data on very large 
numbers of patients are needed (e.g. to detect rare 
adverse reactions), if two (or more) PMS activities 
take place simultaneously, the one may unwantedly 
influence or delay the other [24] and there may even 
be not enough patients in a country to assess all new 
drugs.
In PMS often problems are complex and questions 
difficult to solve. The available information often is 
associated with some uncertainty or is even inconclu­
sive. Interpretation may be influenced by differences 
in opinion and background. Sometimes different con­
clusions may with good reason be attached to one 
and the same set of data.
Medicines are at the same time powerful health 
care instruments and profitable commercial products. 
The findings in PMS play a role in a complex environ­
ment encompassing many different and potentially 
conflicting interests [25] (e.g. commercial profit ver­
sus medical value, economical freedom versus health 
expenditure containment, company property versus 
freedom of information).
When evidence accumulates and knowledge 
increases a change in dose recommendation or indi­
cations for use may be needed, or additional safety 
measures may be required. The findings in PMS may 
impair the commercial value of a drug and in extreme 
situations lead to withdrawal. Even a false alarm may 
cause permanent damage to the drug.
In large countries, after approval the number of 
users of a new medicine may within a short period of 
time become very large. The higher the number of 
users of a drug is, the larger is its commercial value 
but also the possible number of victims of an unfor- 
seen adverse reaction. Pharmacovigilance experts in 
drug companies in European countries are being 
given a personal responsibility in ensuring that data 
on adverse effects are promptly reported to the drug 
regulatory authority [21]. This responsibility should 
not be overruled by instructions in the company. 
Appropriate organisational arrangements in the com­
pany and strict employment contract provisions may 
be necessary to safeguard job security of pharmaco­
vigilance officers.
The basic principle underlying the safe introduction 
of a new medicine is, that whenever a patient uses 
the drug he and his doctor and pharmacists must be 
prepared to (anonymously) participate in the national 
pharmacovigilance program. On the other hand, 
much importance is attached to the principle right of 
any patient to refuse the use of data originating from 
his or her medical history (except for insurance 
accounting purposes) [26]. Proposed new legislation 
in Europe regarding privacy and the confidentiality of 
personal health data is a real threat to future PMS
drug evaluation and are well prepared to contribute, 
provided that commercial (and political) interests are 
excluded. Recent evidence is in support of this view 
[28]. It may be in the future that the public might 
demand effective and transparent surveillance of mar­
keted drugs, in spite of current legislation regarding 
privacy, medical secrecy and drug regulation.
Good Practice
For reasons discussed above there is a need for Good 
Practice in PMS (GPP). Patients contributing data to 
PMS deserve a formal review of the protocol, with 
regard to appropriateness, relevance and ethics. GPP 
starts where GCP ends and should be a logical exten­
sion of the latter. Whereas GCP is predominantly con­
cerned with the rights of individuals, GPP is primarily 
a matter of the public interest. The procedures in all 
activities in the field of PMS need to be as well-consid­
ered and clear as possible. In contrast to a clinical 
trial, in PMS it may be unusual (or impossible) to 
obtain informed consent of the individual patients. 
GPP may be the natural way of solving threatening 
incompatibilities between current legislation and reg­
ulation and the proper performance of PMS. Major 
points of interest in GPP are:
- Scientific principles (aims, methods, procedures, 
inclusion of patients).
- Ethics and legislation (responsibilities, rights and 
interests, privacy and medical secrecy).
- Accounting (protocols, standardization, reporting 
of study results).
- Review: approval of studies and systems (e.g. with 
regard to appropriateness, scientific efficiency and 
ethics), and inspection.
- Setting priorities and allocation of funds.
Current developm ents
Through the years the WHO Collaborating Centre for 
International Drug Monitoring has contributed much 
to the development and harmonisation of the metho­
dology in spontaneous reporting [11 29-31], In a few 
countries, e.g. France and Japan, recently national 
documents on pharmacovigilance have been pre­
pared [32 33]. In addition, various bodies are contrib­
uting to the improvement of the procedures and reg­
ulations in this field. The Council for International 
Organizations of Medical Sciences (CIOMS), for 
example, has advised pharmaceutical companies on 
the international reporting of adverse reactions and 
the production of Drug Safety Updates [34 35] and is 
providing structured definitions of the WHO Critical 
Adverse Reaction Terms [36], The Pharmacovigilance 
Working Party of the European Commission has draft­
ed a number of Guidelines for marketing authoriza­
tion holders, i.e. on adverse reactions reporting [37], 
periodic drug safety update reports [38], company 
sponsored postmarketing safety studies [39], and on­
going pharmacovigilance evaluation during the post- 
marketing period [40]. The new MEDDRA terminolo­
gy for adverse drug reactions (Medical Dictionary for 
Drug Regulatory Affairs [41]) is under consideration 
for adoption in the global scheme of the WHO 
Collaborating Centre in Uppsala, Bénichou and co-
[27]. My personal impression is, however, that mod- workers have developed a series of structured etiolog- 
ern patients think largely positively of postmarketing ic-diagnostic assessment schemes for important or
frequent drug-induced disorders [42 43], Although 
primarily focused on the pre-registration phase, parts 
of the work the Conference on international 
Harmonization (ICH) are also relevant to PMS [44]. 
The European Pharmacovigilance Research Group is 
working on a variety of mainly scientific issues in 
pharmacovigilance [45]. In the United Kingdom a 
code of behaviour in company-sponsored drug safety 
studies has been laid down in collaboration with the 
Medicines Control Agency in the Safety Assessment of 
Marketed Medicines SAMM Guidelines [46]. More 
recently an excellent framework for conducting phar- 
macoepidemiologic studies has been developed by 
the International Society for Pharmacoepidemiology 
ISPE in the Guidelines for Good Epidemiology 
Practices for Drug, Device and Vaccine Research in the 
United States [33]. These and other activities are 
already anticipating GPP.
The next steps
For the further development of GPP, the following 
points need to be addressed:
1. To define the aims of PMS and to identify appro­
priate methods of data collection and assessment 
for the various aims and their specific advantages 
and limitations.
2. To design, standardise and describe in detail the 
methods and procedures for the collection, assess­
ment and distribution of data (spontaneous 
reporting and other).
3. To identify the interests, rights and responsibilities 
of all parties involved: individuals (patients, doc­
tors, pharmacists, investigators) and institutions 
(companies, governmental bodies, patients as a 
group).
4. To design protocols for the reporting (accounting) 
of data and findings, and to develop appropriate 
software for data processing.
5. To prepare a guideline for a data management 
code, specifying which data are available to 
whom, for which purpose, and under which con­
ditions, and also referring to confidentiality.
6. To develop strategies for assessing quality and 
performance of PMS systems.
7. To establish an authoritative forum for the statisti­
cal review of pharmacoepidemiologic studies.
8. To audit in PMS.
9. To ensure professional autonomy (and job secur­
ity) of pharmacovigilance officers.
10.To establish national 'Ethical PMS Committees' (or 
regional in large countries), for the coordination 
and review of the activities pertaining to points 1-
9, especially with regard to:
- appropriateness of protocols and procedures,
- allocation of funds and setting priorities (with 
regard to study subjects),
- enforcement of GPP rules,
- protection of public health interest.
For spontaneous reporting systems the description in 
detail is needed of the appropriate procedures in the 
collection, processing, assessment and dissemination 
of data. The success of a spontaneous reporting 
system depends upon the quantity and quality of 
adverse reaction reporting, the organisation of the 
system, and the utilization of the collected data. With
regard to the level of reporting (input) the following 
criteria may be used:
- Reporting rate (e.g. number of case reports/106 
inhabitants/year).
- Reporting distribution, i.e. the percentage of physi­
cians reporting and reporter characteristics (e.g. 
general practitioners, specialists, pharmacists).
- Reporting quality (e.g. according to the new WHO 
documentation grading [48]).
- Reporting efficiency (the proportion of relevant 
case reports, e.g. concerning unknown or serious 
reactions).
Drug utilization data are useful as a reference, e.g. 
while assessing reporting rates and differences or 
changes in reporting. Regarding the organisation of a 
pharmacovigilance centre it is of interest how the 
system for data acquisition is structured. The profes­
sional expertise of assessors and the mean assessment 
time per case report (or the number of staff members 
per 1000 case reports) may be used as parameters of 
the quality of data assessment at a centre. The budget 
available for pharmacovigilance and the sources and 
continuity of funding indirectly give information 
regarding organisational development.
The yearly numbers and the content of publica­
tions and changes in data sheets referring to sponta­
neous reporting, may be used as indicators of the util­
isation of pharmacovigilance data (output). The fre­
quency of data base searches is another possible 
parameter in this respect Also a data management 
code can give information of data utilisation in a 
country.
Similarly, concrete and detailed guidelines are 
needed for all other activities in PMS. For the - nation­
al and international - establishment of GPP collabora­
tion is needed from medical and pharmaceutical asso­
ciations, academia, regulators and pharmaceutical 
companies. The support of authoritative institutions 
such as the World Health Organization may improve 
international harmonisation and acceptance. The 
public health interest in effective PMS is obvious. 
Since the necessary data have to come from the drug- 
using population at large, the willingness of individual 
patients to contribute is crucial. Patients are at the 
same time the source and the ultimate destination of 
information in PMS. Consumer and patient organisa­
tions should therefore also play a role in the develop­
ment of GPP and the establishment of Ethical PMS 
Committees. As is always true in medicine, also in 
GPP the interest of the patients must come first.
1 gratefully acknowledge the valuable comments of 
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